Popular Articles

Skull Fusion Disorder Of Infants: UC Davis Bioengineer Receives Hartwell Grant
With support from a foundation that champions cutting-edge medical research, a biomedical engineer at UC Davis will start work this month on developing a new treatment for infants born with disorders that cause the sutures of their skulls to prematurely fuse together.
new payday loan lenders
Buy zoloft and forget about depression.
Approval For Use Of RISPERDAL CONSTA As Both A Monotherapy And Adjunctive Therapy In The Maintenance Treatment Of Bipolar I Disorder Granted By FDA
Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder.
News of the day
Small Businesses, Doctors Voice Concerns About Health Reform
"Small business is suddenly playing a big role in negotiations over health care," NPR reports. "Supporters and opponents of various plans to overhaul the system are all trying to paint themselves as champions of mom and pop entrepreneurs." The National Federation of Independent Business is "not happy with the health care bill taking shape in the House this week - especially its requirement for all but the smallest employers to provide health insurance or pay a penalty." Meanwhile, "the Democratic National Committee quickly lined up its own panel of small business owners to defend the House plan."
Mental Health

Proteins In Gel

Several thousand test fields are tightly packed together on the tiny surface of a biochip. They permit the rapid analysis of substances, e.g. for diagnosing allergens in the blood. These biochips are already in widespread use for DNA testing. When it comes to proteins, such chips are difficult to produce. This is because the proteins have a defined three-dimensional structure by which they can interact specifically with other molecules and control biological processes. If they bind to a surface, such as on a biochip, the structure can be destroyed and the protein cannot perform its function. Research scientists at the Fraunhofer Institute for Applied Polymer Research IAP in Potsdam-Golm have solved this problem. "We have developed a gel - a network of organic molecules - that we can apply to the surface of the biochip," says Dr. Andreas Hollç¤nder, group manager at the IAP. "This gel layer is only about 100 to 500 nano-meters thick and consists mainly of water. We thus make the protein believe that it is in a solution, even though it is chemically connected to the network. It feels as if it is in its natural environment and continues to function even though it is on a biochip." Other research groups are working on similar hydrogels. The key feature of the new production technique is that it can be applied in industry, and the gel layers can be manufactured cheaply on a large scale. Usually there are two ways of producing such networks. In the first, complete polymers are chemically bound to the surface. In the second, the polymer molecules are constructed unit by unit on the surface. "Our technique is a mixture of the two known methods. We use larger molecular building blocks to build up the network on the surface," explains Falko Pippig, who is doing his doctorate on this subject at the IAP. As the hydrogel layers are very thin, substances added from the outside very quickly reach the protein which is in and on this layer. For example, physicians can put blood or urine on the chip and diagnose illnesses. The research scientists have already developed the process fundamentals. Protein biochips could therefore become everyday items of equipment in medical laboratories - the possible applications far exceed those of DNA chips. Dr. Andreas Hollaender Fraunhofer-Gesellschaft


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):